EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Factor-inhibiting HIF (FIH) promotes lung cancer progression

Ana García-Del Río, Endika Prieto-Fernández, Leire Egia-Mendikute, Asier Antoñana-Vildosola, Borja Jimenez-Lasheras, So Young Lee, Adrián Barreira-Manrique, Samanta Romina Zanetti, Ander de Blas, Paloma Velasco-Beltrán, Alexandre Bosch, Ana M Aransay und 1 weitere

JCI Insight · 2023

DOI: 10.1172/jci.insight.167394 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCI Insight, 2023. Verfasst von Ana García-Del Río und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Immunology and Immunotherapy Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA)…. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Factor-inhibiting HIF (FIH) is an asparagine hydroxylase that acts on hypoxia-inducible factors (HIFs) to control cellular adaptation to hypoxia. FIH is expressed in several tumor types, but its impact in tumor progression remains largely unexplored. We observed that FIH was expressed on human lung cancer tissue. Deletion of FIH in mouse and human lung cancer cells resulted in an increased glycolytic metabolism, consistent with increased HIF activity. FIH -deficient lung cancer cells exhibited decreased proliferation. Analysis of RNA-Seq data confirmed changes in the cell cycle and survival and revealed molecular pathways that were dysregulated in the absence of FIH , including the upregulation of angiomotin ( Amot ), a key component of the Hippo tumor suppressor pathway. We show that FIH -deficient tumors were characterized by higher immune infiltration of NK and T cells compared with FIH competent tumor cells. In vivo studies demonstrate that FIH deletion resulted in reduced tumor growth and metastatic capacity. Moreover, high FIH expression correlated with poor overall survival in non–small cell lung cancer (NSCLC). Our data unravel FIH as a therapeutic target for the treatment of lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungHumansAnimalsMiceMixed Function OxygenasesRepressor ProteinsHypoxia

Stichwörter der Autor:innen

CancerCell BiologyCellular immune responseHypoxia

Substanzen

Mixed Function OxygenasesRepressor Proteins

Autor:innen und Institutionen

  • Cancer Immunology and Immunotherapy Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Bizkaia, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain.
  • Genome Analysis Platform, CIC bioGUNE, Bizkaia Technology Park, Derio, Bizkaia, Spain.
  • Ikerbasque, Basque Foundation for Science, Bilbao, Spain.

Zitieren

APA

García-Del Río, A., Prieto-Fernández, E., Egia-Mendikute, L., Antoñana-Vildosola, A., Jimenez-Lasheras, B., Lee, S. Y., Barreira-Manrique, A., Zanetti, S. R., de Blas, A., Velasco-Beltrán, P., Bosch, A., Aransay, A. M., & Palazon, A. (2023). Factor-inhibiting HIF (FIH) promotes lung cancer progression. JCI Insight. https://doi.org/10.1172/jci.insight.167394

Vancouver

García-Del Río A, Prieto-Fernández E, Egia-Mendikute L, Antoñana-Vildosola A, Jimenez-Lasheras B, Lee SY, et al. Factor-inhibiting HIF (FIH) promotes lung cancer progression. JCI Insight. 2023. doi:10.1172/jci.insight.167394

BibTeX
@article{GarcaDelRo2023,
  author = {García-Del Río, Ana and Prieto-Fernández, Endika and Egia-Mendikute, Leire and Antoñana-Vildosola, Asier and Jimenez-Lasheras, Borja and Lee, So Young and Barreira-Manrique, Adrián and Zanetti, Samanta Romina and de Blas, Ander and Velasco-Beltrán, Paloma and Bosch, Alexandre and Aransay, Ana M and Palazon, Asis},
  title = {Factor-inhibiting HIF (FIH) promotes lung cancer progression},
  journal = {JCI Insight},
  year = {2023},
  doi = {10.1172/jci.insight.167394}
}
Kostenlos starten →